Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
- Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
- Correlation analysis of KRAS mutation results with clinical data.
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
- Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
- A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
- Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
How understandable was the trial content above?
Hard to understand
Easy to understand
